William Poland

Vice President, Integrated Drug Development


Home Office - Americas

About William Poland

Dr. Poland has provided pharmaceutical companies guidance in drug development decisions through scientific and decision-analytic modeling and simulation since he joined Certara in 1998. In over 40 projects for top pharmaceutical companies, he has advised on trial and program design for HCV, HIV, and other therapeutic areas, using integrated treatment adherence, pharmacokinetic, pharmacodynamic, and trial models. Recommendations included go/no-go, doses and regimens, arm sizes, and target populations. In central nervous system diseases, he has used simulations to develop flexible strategies for optimal Phase 2-3 development of multiple drugs with overlapping indications, incorporating market models to value outcomes. In oncology, he has performed and reported population exposure-efficacy and exposure-tolerability analyses for regulatory submissions.

Poland’s research interests include practical viral dynamics modeling, portfolio optimization, and Bayesian adaptive program design trading off efficacy and side effects, for which he is co-author of a patent submission. Before joining Certara, he performed decision analyses for pharmaceutical and other industries at Strategic Decisions Group. He received his Ph.D. in Engineering-Economic Systems from Stanford University in 1994. He has an M.S. from the same department, an M.S. in Operations Research from the University of California at Berkeley, and a B.S. in Engineering and Applied Sciences from Harvard University.